Literature DB >> 8647627

Three-dimensional co-culture of human monocytes and macrophages with tumor cells: analysis of macrophage differentiation and activation.

A Konur1, M Kreutz, R Knüchel, S W Krause, R Andreesen.   

Abstract

Here we report on an experimental system for generating TAM in vitro by culturing human MO and MO-derived macrophages (MAC) within 3-dimensional multicellular tumor spheroids (MCS). MO as well as MO-derived MAC migrate into tumor spheroids and spread throughout the entire spheroid within 16 hr. In contrast, fibroblast-spheroids were not infiltrated. The regular expression of MAC maturation-associated antigens on infiltrating MO was suppressed within MCS of the undifferentiated bladder carcinoma line J82 with regard to carboxypeptidase M (CPM), MAX.3 antigen and CD105. However, MAC within spheroids of highly differentiated papillary RT4 cells failed only the single antigen CD51, whereas MAC expressed the complete maturation-associated phenotype within non-tumorigenic HCV29 spheroids. Interestingly, the suppressive effect of J82 carcinoma cells could only be observed in 3-dimensional but not in monolayer cultures. The J82-MCS induced suppression of CPM and MAX.3 expression was only seen to be operative on infiltrating blood MO: MO first differentiated for 2 days and subsequently co-cultured with J82-MCS showed normal expression of MAX.3 and CPM within the spheroid. Besides the modulation of MAC phenotype, the cytokine response of intraspheroidal MAC was analyzed: upon co-culture MO secreted high IL-1beta and IL-6 but low amounts of TNF-alpha as compared to MAC. This MO typical cytokine pattern remained constant for up to 8 days in culture, again indicating a disturbed MO to MAC maturation within tumor spheroids. In conclusion, a 3-dimensional interaction with tumor cells in vitro results in significant changes in the phenotype and function of the spheroid-associated MO and MAC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8647627     DOI: 10.1002/(SICI)1097-0215(19960529)66:5<645::AID-IJC11>3.0.CO;2-3

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Characterization of MAX.3 antigen, a glycoprotein expressed on mature macrophages, dendritic cells and blood platelets: identity with CD84.

Authors:  S W Krause; M Rehli; S Heinz; R Ebner; R Andreesen
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

2.  Tumors induce the formation of suppressor endothelial cells in vivo.

Authors:  Jennifer Konopa Mulligan; M Rita I Young
Journal:  Cancer Immunol Immunother       Date:  2010-02       Impact factor: 6.968

Review 3.  Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies.

Authors:  Claire Lewis; Craig Murdoch
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

Review 4.  Liquid-based three-dimensional tumor models for cancer research and drug discovery.

Authors:  Stephanie L Ham; Ramila Joshi; Pradip S Thakuri; Hossein Tavana
Journal:  Exp Biol Med (Maywood)       Date:  2016-04-11

5.  Tumors skew endothelial cells to disrupt NK cell, T-cell and macrophage functions.

Authors:  Jennifer K Mulligan; Deanne M R Lathers; M Rita I Young
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968

Review 6.  From Chemotherapy to Combined Targeted Therapeutics: In Vitro and in Vivo Models to Decipher Intra-tumor Heterogeneity.

Authors:  Guido Gambara; Manuela Gaebler; Ulrich Keilholz; Christian R A Regenbrecht; Alessandra Silvestri
Journal:  Front Pharmacol       Date:  2018-02-14       Impact factor: 5.810

7.  Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2.

Authors:  Claire E Lewis; Russell Hughes
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

Review 8.  The Continuing Evolution of Insulin-like Growth Factor Signaling.

Authors:  Steven A Rosenzweig
Journal:  F1000Res       Date:  2020-03-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.